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Developmental endothelial locus-1Coronary heart disease (CHD) is characterized by abnormal intercellular communication and circu-
lating microRNAs (miRNAs) are likely involved in this process. Here, we show that CHD was associ-
ated with changes in the transport of circulating miRNA, particularly decreased miRNA enrichment
in microparticles (MPs). Additionally, MPs from CHD patients were less efﬁcient at transferring miR-
NA to cultured HUVECs, which correlated with their diminished capacity to bind developmental
endothelial locus-1 (Del-1). In summary, CHD was associated with distinct changes in circulating
miRNA transport and these changes may contribute to the abnormal intercellular communication
that underlies CHD initiation and progression.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Atherosclerosis isa chronic inﬂammatorydisease characterizedby
abnormal cellular interactions between leukocytes, platelets, endo-
thelial, and smooth muscle cells. These interactions lead to the pro-
duction of inﬂammatory cytokines, such as tumor necrosis factor
alpha (TNFa) [1], which, in turn, potentiate inﬂammatory signals be-
tween and within cells. Intercellular signaling, therefore, is a critical
aspect of atheroscleroticplaque formation, impactingnotonly the ini-
tiation of coronary heart disease (CHD), but also its progression [2].
MicroRNAs (miRNAs) are short, single-stranded, non-coding
RNAs that modulate intracellular gene expression through post-
transcriptional regulation of targeted mRNAs [3–5]. In vivo and
in vitro studies have demonstrated that extracellular miRNAs, in
a manner suggestive of paracrine or endocrine signaling, can be
shuttled between cells to orchestrate a diverse array of cellular re-
sponses [6–8]. These ﬁndings, together with observations by our
group [9] and others that circulating miRNA levels are altered indifferent pathological states [10–13], point to the importance of
circulating miRNA transport in normal physiology and disease.
Extracellular miRNAs have been identiﬁed in serum and plasma
and are associated with distinct transport modalities, including
encapsulation within membrane-bound vesicles [14–16] (micropar-
ticles, exosomes) or bound to circulating proteins and lipoproteins
[8,17]. Speciﬁc miRNAs have been shown to be preferentially
enriched in particular transport modalities and this enrichment
can be altered by disease [8,16,18,19]. In the present study, we
investigated the impact of coronary heart disease (CHD) on the
transport characteristics of a small subset of miRNAs (eight) whose
abundances are known to be altered in CHD (miR-17, miR-19a, miR-
21, miR-92a, miR-126, miR-146a, miR-222, and miR-223) [20]. Our
ﬁndings indicate that CHD was primarily associated with decreased
miRNA loading of MPs as well as their transmission to recipient
cells, which, taken together, may contribute to the abnormal inter-
cellular signaling that accompanies CHD initiation and progression.
2. Materials and methods
2.1. Sample population
Frozen human serum samples from healthy subjects (n = 27),
patients with signiﬁcant CHD (n = 21) and patients with only
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cular Biobank. Blood from patients with signiﬁcant CHD and indi-
viduals with only CHD risk factors was collected through an
arterial sheath placed during elective cardiac catheterization.
Blood from healthy subjects was collected by venipuncture at the
time of enrollment in the Biobank data base. Healthy donors met
the following criteria: (1) 18–64 yr old; (2) no history of major sys-
temic medical conditions/diseases; (3) no major modiﬁable risk
factors for CHD; (4) no prescription medications or hospitalizations
within one year of serum collection. Patients with signiﬁcant CHD
were individuals with >50% stenosis inP1 epicardial coronary ar-
tery documented by coronary angiogram. Analysis of angiograms
was based on visual estimates by two independent operators,
who utilized the modiﬁed form of the AHA/ACC classiﬁcation of
the coronary tree [21,22]. Patients with only CHD risk factors
exhibited similar clinical characteristics as CHD donors, except
none had an epicardial coronary artery with >50% stenosis. The
clinical characteristics of the three study groups are shown in Ta-
ble 1. The study was approved by the Institutional Review Board
at Emory University, Atlanta, GA, USA. All subjects provided writ-
ten informed consent at the time of enrollment.
2.2. Serum ultracentrifugation
Serum samples were thawed at 37 C. After thawing, serum
was diluted 1:3 with phosphate buffered saline (PBS). Using a
previously described ultracentrifugation protocol [16] (Supple-
mental Fig. S1), diluted serum was separated into four distinct
fractions: a microparticle fraction, an exosome fraction, an aggre-
gated protein fraction that contained miRNAs complexed with
proteins such as Argonaut 2 (Ago2) [17], and a lipoprotein
fraction, containing miRNA–lipoprotein complexes. Fractions
were characterized by ﬂow cytometry for annexin V, CD63, and
CD81 staining in MPs and exosomes; lipid/lipoprotein/apolipo-
protein contamination was determined for each fraction (Supple-
mental Fig. S1).
2.3. Quantitative qRT-PCR analysis for miRNA enrichment
miRNAwas isolated using the commercially available miRNeasy
isolation kit according to manufacturer’s protocol (Qiagen Inc.,
Valencia, CA). miRNA reverse transcription was performed using
the TaqManmicroRNA Reverse transcription Kit (Life Technologies,
Foster City, CA). TaqManmicroRNA assays (Life Technologies) were
performed using the 7500 Fast Real-Time PCR System at the 9600Table 1
Characteristics of study subjects.
Healthy subjects (n = 27)
Gender male 10 (37%)
Race White 17 (63.0%)
Age (years) 46.68 ± 13.86###
Signiﬁcant CHD (>50%) 0###
Hypertension 0###
Active smoker 1 (3.7%)
Adipositas (BMI >25) a 5 (18.5%)###
Diabetes mellitus 0#
History of (AMI, PCI, stroke) b 0###
Concurrent medication
Aspirin/plavix 0###
ACE-inhibitor/ARB 0###
Statin therapy 0###
# P < 0.05.
### P < 0.001 signiﬁcance versus CHD (ANOVA, Bonferroni Post hoc).
a BMI = body mass index.
b PCI = percutaneous coronary intervention.emulation run mode. Quantitative PCR was carried out using a
StepOne real-time thermocycler (Applied Biosystems, San Fran-
cisco, CA). miRNA detection was performed using speciﬁc primer
pairs and TaqMan probes, which were predesigned by Applied Bio-
systems. Fluorescence data were quantiﬁed using the mak3 mod-
ule of the qpcR software library in the R environment [23–25].
Quantitative results were normalized to the average values of
miR-346 as an internal control. This miRNA was found suitable
for normalization because it met the threshold level of gene vari-
ability [26] and presented minimal changes between different dis-
ease samples and serum fractions (Supplemental Fig. S2). miRNA
abundance in a particular serum fraction was calculated by divid-
ing the normalized quantitative levels of miRNA in a particular ser-
um fraction by the sum of the normalized quantitative levels of the
same miRNA obtained for all four serum fractions [% of
Total = (miRNAserum fraction x/
P
miRNAall serum fractions)  100].
2.4. qRT-PCR analysis for miRNA relative expression
Reverse transcription was performed on miRNA isolated from
serum using the TaqMan microRNA Reverse transcription Kit. Ct
Values of the analyzed miRNAs were converted into relative
expression levels (relative expression = 2(Ct)). Normalized relative
expression values for miRNAs were calculated by dividing the rel-
ative expression of each miRNA by the relative expression obtained
for miR-346.
2.5. Transfer of circulating miRNA to cultured human endothelial cells
Human umbilical vein endothelial cells (HUVECs), passages 2–5,
were grown on 75 cm2 cell culture ﬂasks (Corning Inc., Corning,
NY). Cells were split onto 6-well cell culture plates (Corning)
1 day prior to miRNA transfer experiments. On the day of experi-
ments, cell conﬂuence was conﬁrmed by visual estimation and
media in each well was replaced with 1 mL of fresh medium in
addition to 100 lL of MPs (re-suspended in PBS) or PBS (as con-
trol). HUVECs were incubated at 37 C for 2 h. After incubation,
media was removed and HUVECs were washed rigorously with
PBS then harvested. miRNA was isolated from HUVECs using the
mirVana miRNA isolation kit (Life Technologies) according to man-
ufacturer’s protocol and relative miRNA expression was quantiﬁed
using qRT-PCR analysis. Intracellular miR-223 and miR-92a abun-
dance in treated HUVECs was represented as a fold change over
the miRNA abundance measured in HUVECs that were incubated
with PBS only. Transfer index was deﬁned as intracellular miRNASigniﬁcant CHD (n = 21) CHD risk factors only (n = 20)
12 (57%) 8 (40%)
16 (76.2%) 15 (75%)
64.14 ± 11.75 58.60 ± 9.31
100% 0###
16 (76.2%) 15 (75.0%)
1 (4.8%) 1 (5.0%)
16 (94.1%) 20 (100%)
7 (33.3%) 4 (20%)
13 (61.9%) 1 (5%)###
20 (95.2%) 17 (85%)
19 (90.5%) 16 (80%)
19 (90.5%) 15 (75%)
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of the same miRNA as measured in a 100 lL volume of MPs.
2.6. ELISA for circulating Del-1 in human sera
A commercially available sandwich ELISA kit for developmental
endothelial locus-1 (Del-1) (Cusabio via Antibodies-Online, Atlan-
ta, GA) was used, according to manufacturer’s protocol, to assess
circulating Del-1 levels in unfractionated human sera.
2.7. Flow cytometry analysis of microparticles
Using 10 lm Flow-Count ﬂuorescent beads (Beckman Coulter),
MPs were counted by ﬂow cytometry, according to the previously
described protocol [27]. Del-1 expression in MPs isolated from
human sera was assessed as previously described [28]. In brief,
MPs were incubated with a primary antibody to Del-1 (rabbit poly-
clonal EDIL3, Abcam, Cambridge, MA), followed by a FITC-tagged
secondary antibody (goat polyclonal anti-rabbit, Abcam). FITC
mean ﬂuorescence intensity (MFI) was analyzed by ﬂow cytometry
and results were reported as MFI per MP count. In order to quantify
available phosphatidylserine (PS) on serumMPs, isolated MPs were
labeled with FITC-tagged annexin V (BD Biosciences, San Jose, CA).
FITC MFI was subsequently analyzed by ﬂow cytometry, and the
results were reported as MFI per MP count.
2.8. Quantiﬁcation of microparticle interaction with recombinant
Del-1
MPs isolated from human sera were incubated with varying
concentrations of recombinant Del-1 (R&D Systems) for 30 min
at 37 C. Subsequently, MPs were incubated with FITC-labeled an-
nexin V, according to manufacturer’s protocol (BD Biosciences).
FITC MFI was quantiﬁed via ﬂow cytometry. Results were re-
ported as MFI per MP count and plotted as a function of initial re-
combinant Del-1 concentration (lg Del-1/MP) to produce a Del-1
binding curve. To quantify the relative efﬁciency of the Del-1/MP
interaction, the slope of the linear region of the Del-1 binding
curve was calculated using GraphPad Prism statistical software
tools.
2.9. Statistical analysis
Statistical analyses were performed using the GraphPad Prism
software package (GraphPad Software Inc, LaJolla, CA). Values are
expressed as means ± S.E.M. Statistical tests, including the un-
paired Student t test, analysis of variance (ANOVA) and the Bonfer-
roni Post hoc test were used to compare data. P 6 0.05 was
considered statistically signiﬁcant.3. Results
3.1. CHD-associated abnormalities in miRNA distribution are exhibited
primarily in microparticles
Coronary heart disease (CHD) is associated with changes in cir-
culating levels of miRNA [20], so we examined whether the distri-
bution of miRNAs across different transport modalities was also
affected by disease. CHD-associated differences in miRNA distribu-
tion were detected for seven out of eight miRNAs assessed; these
differences were observed primarily in the microparticle (MP) frac-
tion of human sera (Fig. 1). The enrichment of miR-17, -19a, -21, -
92a, -146a, -222, and -223 in MPs was signiﬁcantly lower in serum
obtained from CHD patients compared to serum obtained from
healthy subjects or patients with CHD risk factors only. For thethree groups assessed, miR-126 was the only miRNA that showed
no signiﬁcant differences in distribution across all four circulating
miRNA transport modalities. Interestingly, several miRNAs that
had similar levels in unfractionated sera of healthy subjects com-
pared to patients with signiﬁcant CHD (Supplemental Fig. S3)
showed signiﬁcant differences in their distribution across distinct
fractions (Fig. 1). Taken together, these results show that signiﬁ-
cant CHD was associated with changes in the transport proﬁle of
miRNAs, and these changes were observed predominantly in the
MP fraction.
Although there were differences in miRNA distribution between
healthy subjects and patients with signiﬁcant CHD, no such differ-
ences were seen between healthy subjects and patients with CHD
risk factors only (Fig. 1). Moreover, differences in miRNA distribu-
tion were detected between patients with CHD risk factors only
and those with signiﬁcant CHD. Taken together, these ﬁndings sug-
gest that miRNA distribution was associated with disease progres-
sion, as opposed to differences in age, gender, or medication. For
this reason, subsequent analysis included healthy subjects and pa-
tients with signiﬁcant CHD. This allowed the use of extreme cases,
in terms of CHD phenotype, to assess the impact of disease on cir-
culating miRNA transport.
3.2. CHD is associated with decreased miRNA loading of circulating
MPs
Circulating MPs are thought to play a role in intercellular signal-
ing because they contain a variety of biological components,
including proteins and RNA molecules [29], and can effectively
transfer these components from one cell type to the next [30–
32]. Here, CHD-associated decreases in miRNA enrichment were
seen primarily in the MP fraction of human serum; this phenome-
non occurred largely in the absence of signiﬁcant increases in miR-
NA enrichment in the other fractions. One possible explanation for
this observation is decreased miRNA loading of circulating MPs in
patients with CHD. We found that for a majority of the miRNAs
studied, miRNA content per MP was signiﬁcantly decreased in
MPs isolated from the sera of patients with signiﬁcant CHD,
(Fig. 2). These data suggest that the CHD-associated decrease in
miRNA enrichment of the MP fraction was due to decreased miRNA
loading of circulating MPs.
3.3. MiRNA transfer from microparticles to cultured HUVECs
To test whether miRNA-containing MPs isolated from human
sera can transmit miRNA to recipient cells, human umbilical vein
endothelial cells (HUVECs) were incubated with serum-isolated
MPs for 2 h (Fig. 3A). We utilized qRT-PCR analysis to assess the
transmission of miRNA from isolated MPs to cultured HUVECs.
The 2 h time point was chosen to minimize the possibility of MP-
induced changes in miRNA transcription that are independent of
MP uptake, which can occur within a 4–8 h time period [33]. Intra-
cellular levels of miR-92a and miR-223 were assessed in treated
HUVECs. MiR-92a and miR-223 were chosen because of their high
expression levels in serum (Supplemental Fig. S4). Intracellular lev-
els of miR-92a and miR-223 were higher in HUVECs treated with
MPs compared to HUVECs treated with PBS (Fig. 3A), thus support-
ing transfer of MP content to cultured HUVECs.
Next, we assessed whether MPs from healthy subjects, com-
pared to MPs from patients with signiﬁcant CHD, differed in their
ability to transmit miRNA to cultured HUVECs. MPs from healthy
subjects or CHD patients, respectively, were incubated with cul-
tured HUVECs for 2 h. In parallel, relative miRNA expression levels
were measured in MPs isolated from healthy subjects and CHD pa-
tients, respectively. After incubation, uptake of miR-92a and miR-
223 was assessed. MPs isolated from CHD patients had a signiﬁ-
Fig. 1. Circulating miRNA distributions across distinct serum fractions. Serum samples were obtained from healthy subjects (n = 8, black bars), individuals with risk factors
for CHD (n = 8, pink bars) and individuals with signiﬁcant CHD (n = 8, red bars) were separated into distinct fractions: MP – microparticles; Exo – exosomes; AP – aggregated
proteins; LP – lipoprotein. MiRNA was isolated from the fractions and quantiﬁed by qRT-PCR analysis; miR-346 was used for normalization. MiRNA abundance in each
fraction was calculated as described in materials and methods and is represented as % of total miRNA. #P < 0.05, ##P < 0.01 (ANOVA, Bonferroni Post hoc). CHD risk factor
group and signiﬁcant CHD group were not signiﬁcantly different in terms of age, gender, CHD risk factors and medications.
N.A. Finn et al. / FEBS Letters 587 (2013) 3456–3463 3459cantly lower capacity for transfer miR-92a and miR-223 to cul-
tured HUVECs compared to MPs isolated from healthy subjects
(Fig. 3B).
3.4. MPs from CHD patients have less Del-1
The decreased ability of MPs isolated from patients with signif-
icant CHD to transfer miRNA to cultured HUVECs suggests that MP
uptake was impaired in the disease state. Developmental endothe-
lial locus-1 (Del-1) is a 52-kDa bridging glycoprotein (also known
as EDIL3) that is secreted by endothelial cells [34]. Del-1 has been
shown to mediate endothelial uptake of MPs, in vivo, via a phos-
phatidylserine-mediated mechanism [28]. To investigate whether
CHD is associated with changes in Del-1 expression, levels of
Del-1 in unfractionated sera were assessed. We found a signiﬁ-
cantly higher amount of Del-1 in the sera of CHD patients
(3.9 ± 0.2 pg/mg total protein) than we did in the sera of healthy
subjects (2.9 ± 0.1 pg/mg total protein; P < 0.05) (Fig. 4A). How-
ever, when we used ﬂow cytometry to measure Del-1 bound to
the surface of MPs isolated from human sera, we found that MPs
from CHD patients had signiﬁcantly less Del-1 bound than MPs
from healthy subjects (Fig. 4B).
Del-1 binds to phosphatidylserine on the external surface of
MPs, which is an important part of the mechanism by which it
mediates MP uptake by endothelial cells [35,36]. Based on the ob-
served differences in Del-1 bound to MPs, we hypothesized thatMPs from CHD patients would have more available PS on their sur-
face. The abundance of available (i.e. unbound) phosphatidylserine
on the surface of MPs isolated from healthy subjects and CHD pa-
tients, respectively, was assessed by annexin V staining and ﬂow
cytometry analysis. MPs isolated from CHD patients had a signiﬁ-
cantly higher amount of available PS compared to MPs isolated
from healthy subjects (Fig. 4C).
These results suggest that even in the presence of increased con-
centrations of circulating Del-1, MPs from sera of CHD patients did
not bind to circulating Del-1 as efﬁciently as did MPs from healthy
subjects. To further examine this possibility,we incubatedMPs from
CHD patients and healthy subjects, respectively, with increasing
concentrations of recombinant Del-1. After Del-1 incubation, MPs
were stained with FITC-labeled annexin V to assess the amount of
unbound PS that remained on surface of theMPs. The resulting ﬂow
cytometry histograms revealed distinct annexin binding responses
forMPs isolated fromCHDpatients compared to those isolated from
healthy subjects (Fig. 5A). MPs from healthy subjects, when incu-
batedwith increasing concentrations of recombinantDel-1, showed
an abrupt decrease in ﬂuorescence at concentrations above 0.4 lg/
ml Del-1, suggesting saturation of Del-1 binding above this concen-
tration. In contrast,MPs fromCHDpatients exhibited amore gradual
decrease in ﬂuorescence, which only appreciably changed above a
Del-1 concentration of 0.8 lg/ml.
Binding curves describing the relationship between average
ﬂuorescence per microparticle and Del-1 concentration were gen-
Fig. 2. MPs isolated from CHD patients are loaded with less miRNA compared to MPs isolated from healthy subjects. miRNA loading in MPs was calculated by dividing relative
miRNA expression by average MP count, as described in Materials and Methods (healthy, n = 8; CHD, n = 8). #P < 0.05, ##P < 0.01 (Student t test).
Fig. 3. MPs from healthy subjects transfer miRNA to cultured endothelial cells more
efﬁciently than MPs from CHD patients. (A) MP-mediated miRNA transfer to
cultured HUVECs. HUVECs were incubated at 37 C for 2 h with MPs obtained from
the sera of healthy subjects or with PBS (as control). After incubation, intracellular
levels of miR-92a and miR-223 were quantiﬁed using qRT-PCR analysis. (B) Impact
of CHD onMP-mediated miRNA transfer. HUVECs were incubated with MP obtained
from the sera of healthy subjects or patients with signiﬁcant CHD. After incubation,
HUVECs were harvested and intracellular miR-92a and miR-223 were assessed. The
miRNA transfer index was calculated from qRT-PCR-based measurement of
intracellular miRNA abundance, as described in Section 2 (Healthy n = 4, CHD
n = 4 for panels A,B). #P < 0.05 (Student t test), ⁄P < 0.05 (ANOVA, Bonferroni Post
hoc).
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of the curve was taken as an estimate of the efﬁciency of recombi-
nant Del-1 binding to PS on MPs (Fig. 5B). The binding efﬁciency ofrecombinant Del-1 was signiﬁcantly less for MPs isolated from
CHD patients (slope = 17.1 ± 3.8) compared to MPs isolated from
healthy subjects (slope = 34.44 ± 3.1; P < 0.05), indicating that
MPs from CHD patients interact less avidly with Del-1 compared
to MPs from healthy subjects. This ﬁnding offers a potential mech-
anism for the difference in MP-mediated miRNA transfer that was
observed between MPs from healthy subjects and CHD patients:
Del-1 binding to MPs is impaired in CHD sera, thereby leading to
decreased uptake by recipient cells.
4. Discussion
Selective packaging of miRNAs into distinct transport modali-
ties is likely an important factor in the biological function of se-
creted miRNAs [8,37]. Here, we show that CHD, a disease that is
characterized by abnormal cell-to-cell communication, altered cir-
culating miRNA transport. In particular, this study is the ﬁrst to
demonstrate CHD-associated changes in miRNA distribution across
different circulating miRNA transport modalities. Moreover, we
show that CHD was associated with diminished miRNA loading
into MPs and miRNA transfer from MPs to recipient cells.
The mechanisms responsible for the uptake of extracellular
miRNAs from the circulation are dependent on speciﬁc molecular
interactions. For example, the uptake of miRNA bound to HDL is
mediated through the scavenger receptor class B type I (SR-BI)
[8]. Additionally, the glycoproteins Del-1 and lactedherin mediate
the clearance of circulating MPs by endothelial cells and splenic
macrophages, respectively, via bridging interactions with avb3
Fig. 5. MPs from CHD patients interact abnormally with recombinant Del-1 protein. (A) Binding of recombinant Del-1 to MPs from healthy subjects and patients with
signiﬁcant CHD. MPs from healthy subjects or CHD patients were incubated with increasing concentrations of recombinant Del-1 protein then stained with FITC-labeled
annexin V; representative ﬂow cytometry histograms are shown. (B) Binding efﬁciency of recombinant Del-1 to MPs from healthy subjects and patients with CHD. The slope
of the linear region of the Del-1 binding curve (showing the 95% CI) estimates the efﬁciency of Del-1 binding to PS on MPs. (n = 10 for each group in panel A; n = 12 for each
group in panel B (pooled samples). #P < 0.05 (Student t test).
Fig. 4. MPs from CHD patients have altered Del-1 expression compared to MPs from healthy subjects. (A) Del-1 in whole sera. The concentration of circulating Del-1 in whole
sera from healthy subjects and CHD patients, respectively, was analyzed using a sandwich ELISA kit. (B) Del-1 expression on surface of circulating MPs. MPs isolated from
healthy subjects and CHD patients were incubated with a primary antibody to Del-1 followed by a FITC-tagged, anti-rabbit secondary antibody. FITC mean ﬂuorescence
intensity (MFI) was analyzed by ﬂow cytometry (left: histogram proﬁles; healthy = ﬁlled black; CHD = ﬁlled red; PBS control = dotted line; right: mean grouped data ± S.E.M).
(C) Available phosphatidylserine on surface of MPs of circulating MPs. MPs isolated from healthy subjects and CHD patients were incubated with a primary antibody to
Annexin V followed by a FITC-tagged, anti-rabbit secondary antibody. FITC mean ﬂuorescence intensity (MFI) was analyzed by ﬂow cytometry. Right panel is mean grouped
data ± S.E.M. n = 6 For each group in panels A and B; n = 4 for each group in panel C. #P < 0.05 (Student t test).
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Fig. 6. Schema of the proposed impact of coronary heart disease on miRNA-mediated intercellular communication. CHD impacts miRNA-mediated intercellular
communication via three mechanisms: (i) by decreasing miRNA loading of MPs, (ii) by altering Del-1 binding to MPs, and (iii) by decreasing MP uptake. Altered miRNA proﬁle
of MPs and decreased miRNA content in MPs suggests CHD-associated abnormalities within the donor cell. Impaired MP uptake is likely to impact the behavior and function
of the target cell.
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that MPs facilitate the transfer of circulating miRNA between cells
[38,39], changes in the membrane composition of MPs likely inﬂu-
ence miRNA-mediated intercellular communication.
In this study, we present data suggesting that CHD altered the
membrane interactions of circulating MPs, leading to impaired
MP-mediated miRNA transfer. Despite increased circulating levels
of Del-1 in patients with CHD, there was less Del-1 bound to
MPs from these patients. Recombinant Del-1 demonstrated a lower
afﬁnity for MPs from CHD patients compared to those from healthy
subjects, indicating that CHD-associated alterations in MP function
(i.e. interaction with Del-1) were at least partly responsible for dif-
ferences in miRNA transfer to endothelial cells. It is also possible
that CHD is associated with a defect in Del-1, although this was
not assessed here. Further studies are required to fully characterize
the impact of CHD on the morphological properties and surface
protein composition of circulating MPs.
Although the results presented in this study offer a novel mech-
anism by which coronary heart disease alters miRNA-mediated
intercellular communication, it is important to note the study’s
limitations. Firstly, the subset of miRNAs that were assessed re-
ﬂects only a select group of miRNAs and is by no means exhaustive.
A high-throughput screening of more miRNAs is likely to reveal
additional information about the effects of CHD on extracellular
miRNA transport. Secondly, a repository of frozen human serum
was utilized to develop protocols that focused on assessing extra-
cellular miRNA transport. Although the freezing process did not in-
duce signiﬁcant losses in miRNA (Supplemental Fig. S5), serum
storage at low temperatures has been associated with a decrease
in annexin V+ labeled MPs. While this phenomenon is expected
to equally affect all of the groups examined in the current study,
the effect of freezing could potentially bias the MP population
being analyzed by preferentially depleting annexin V+ labeled
MPs [40].
Given the mechanism by which MPs are formed, the cellular
source of circulating MPs is likely to be another factor that impacts
MP surface composition [38,39] and therefore the ability of MPs to
transfer miRNA to recipient cells. We conducted a preliminary
assessment of the cellular origin of circulating MPs in the sera of
healthy subjects (Supplemental Fig. S6) that indicated most MPs
originate from platelets and red cells, with less than 20% originated
from ECs and monocytes. However, a more in-depth analysis of thecellular origin of circulating MPs will be necessary to fully under-
stand the impact of CHD on miRNA-mediated intercellular com-
munication. Future studies will need to characterize not only the
cellular source of the circulating microparticles and exosomes,
but also how export of miRNAs from these cellular sources may
be affected by disease progression.
The current study focused on serum, but there are likely differ-
ences in the MP population present in serum compared to that in
plasma. Our analysis of plasma samples from healthy subjects
and CHD patients showed that CHD-associated decreases in miRNA
loading of MPs were also observed in plasma samples (Supplemen-
tal Fig. S7). Moreover, other studies have shown that miRNA levels
are comparable between serum and plasma [10]. Nonetheless, a
more comprehensive analysis of the effect of sample preparation
and storage will be necessary to extrapolate the current ﬁndings
to a diverse array of biological ﬂuids.
In summary, the transfer of miRNA from one cell to another via
the circulation is dependent on how circulating miRNAs are trans-
ported. CHD was associated with distinct changes in extracellular
miRNA transport which can impact miRNA-mediated intercellular
communication (Fig. 6). The current study focused on the role of
MPs, but, the impact of CHD on other miRNA transport modalities
should not be ignored. Currently, there is a limited understanding
of the molecular mechanisms that regulate miRNA sorting and ex-
port, and as a result, there may be unknown levels of connectivity,
or inhibition, between the pathways that are responsible for extra-
cellular miRNA transport. Future work will need to elucidate dis-
ease-associated molecular mechanisms responsible for the
sorting and release of miRNAs into the circulation. The identiﬁca-
tion of the mechanisms responsible for disease-associated altera-
tions in miRNA transport will likely enhance the use of
extracellular miRNAs as biomarkers and novel therapeutics for
disease.
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